B Cell News and Research

RSS

UTHSC investigators secure $2.16 million to test a new way to combat neurodegenerative disorders

The National Institute on Aging recently awarded $2.16 million to a team of investigators from the University of Tennessee Health Science Center (UTHSC) testing a new way to combat the root cause of neurodegenerative disorders such as Alzheimer's Disease.

22 Jul 2022

Maternal antibodies may play a key role in protecting infants from congenital HCMV infections

Antibodies that summon virus-engulfing white blood cells may play an important role in protecting infants from potentially serious congenital infection with human cytomegalovirus (HCMV), according to a study led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian.

22 Jul 2022

NIH grant awarded to Marshall researcher for studying genetic mechanisms of cocaine addiction

Price E. Dickson, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has received a $407,000 grant from the National Institutes of Health to study the genetic and genomic mechanisms driving the relationship between social reward and cocaine addiction.

22 Jul 2022

Improving the immune defenses against blood cancer

For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer.

22 Jul 2022

Researchers discover a ‘weak spot’ that makes multi-drug resistant tumors vulnerable

One of the greatest challenges facing cancer researchers is to understand why some patients don't respond to treatments.

22 Jul 2022

New biomimetic formulation developed to tackle glioblastoma multiforme

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore urgently needed.

22 Jul 2022

Antibodies' neutralization efficacy against Omicron variants BA.1 And BA.2 wanes rapidly, study finds

The Omicron variant of the SARS-CoV-2 virus was first detected in South Africa in November 2021. The high level of infectiousness of the virus and its ability to quickly spawn additional variants has also been observed in Germany: Since January 2022 the Omicron variant BA.1 has dominated here, followed in subsequent months by the variant BA.2.

22 Jul 2022

Study examines the maintenance of immunity to SARS-CoV-2 after natural infection or post-vaccination

A new study examined the maintenance of memory B cell responses to SARS-CoV-2, the virus that causes COVID-19, after recovery from natural infection or post-vaccination.

22 Jul 2022

Oligomeric molecular structure of the MOR-Gal1R complex revealed

A study published in the journal Pharmacological Research reveals the oligomeric molecular structure of the MOR-Gal1R complex, a component present in the brain which is involved in the analgesic and addictive effects of certain opioids.

22 Jul 2022

Study opens up new possible treatment methods for patients with urinary tract infections

Patients who have indwelling urinary catheters often suffer from urinary tract infections, which can be difficult to treat.

22 Jul 2022

LJI study about common cold coronaviruses may offer clues to how immunity can build up against SARS-CoV-2

For a glimpse into the future of SARS-CoV-2 immunity, scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system builds its defenses against common cold coronaviruses (CCCs).

21 Jul 2022

Researchers discover a concise way to synthesize potent natural neurotoxin

Researchers have discovered a concise way to synthesize a "biosynthetic and ecological enigma" that has intrigued chemists and biologists for more than a century: tetrodotoxin (TTX), a potent natural neurotoxin commonly associated with pufferfish that is also used as a vital probe in neuroscience research.

21 Jul 2022

Study may help overcome some obstacles to the development of nanoparticle-based drugs

Using nanoparticles to deliver cancer drugs offers a way to hit tumors with large doses of drugs while avoiding the harmful side effects that often come with chemotherapy.

21 Jul 2022

A different approach to build a more durable, broadly effective COVID-19 vaccine

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe a different way to build a COVID-19 vaccine, one that would, in theory, remain effective against new and emerging variants and could be taken as a pill, by inhalation or other delivery methods.

21 Jul 2022

Cancer cells produce small amount of collagen that impacts tumor microbiome and immunity

Cancer cells produce small amounts of their own form of collagen, creating a unique extracellular matrix that affects the tumor microbiome and protects against immune responses, according to a new study by researchers at The University of Texas MD Anderson Cancer Center.

21 Jul 2022

Booster vaccination counters the severity of Omicron breakthrough infections

Researchers assessed a panel of seven SARS-CoV-2 vaccines currently available globally and in the United States and immunity acquired through the previous infection against all Omicron subvariants.

21 Jul 2022

FDA clears IND application for MD Anderson-sponsored Phase I clinical study of OBX-115 therapy

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian's lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.

21 Jul 2022

B Cell News and Research

UTHSC investigators secure $2.16 million to test a new way to combat neurodegenerative disorders

Maternal antibodies may play a key role in protecting infants from congenital HCMV infections

NIH grant awarded to Marshall researcher for studying genetic mechanisms of cocaine addiction

Improving the immune defenses against blood cancer

Researchers discover a ‘weak spot’ that makes multi-drug resistant tumors vulnerable

New biomimetic formulation developed to tackle glioblastoma multiforme

Antibodies' neutralization efficacy against Omicron variants BA.1 And BA.2 wanes rapidly, study finds

Study examines the maintenance of immunity to SARS-CoV-2 after natural infection or post-vaccination

Oligomeric molecular structure of the MOR-Gal1R complex revealed

Study opens up new possible treatment methods for patients with urinary tract infections

LJI study about common cold coronaviruses may offer clues to how immunity can build up against SARS-CoV-2

Researchers discover a concise way to synthesize potent natural neurotoxin

Study may help overcome some obstacles to the development of nanoparticle-based drugs

A different approach to build a more durable, broadly effective COVID-19 vaccine

Cancer cells produce small amount of collagen that impacts tumor microbiome and immunity

Booster vaccination counters the severity of Omicron breakthrough infections

FDA clears IND application for MD Anderson-sponsored Phase I clinical study of OBX-115 therapy

Pigment epithelium-derived factor ablations may lead to eye aging

Unlocking the power of proteins to better understand human health

Is monkeypox a global public-health emergency?

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News